Iqvia (IQV) Receives Hold Rating from SunTrust Banks

Iqvia (NYSE:IQV)‘s stock had its “hold” rating reiterated by stock analysts at SunTrust Banks in a research note issued to investors on Monday. They currently have a $110.00 price target on the medical research company’s stock. SunTrust Banks’ target price would suggest a potential upside of 5.99% from the stock’s current price.

IQV has been the topic of several other research reports. KeyCorp reiterated a “sector weight” rating and set a $100.00 target price on shares of Iqvia in a research report on Friday, November 10th. Credit Suisse Group reiterated an “outperform” rating and set a $110.00 target price (up previously from $98.00) on shares of Iqvia in a research report on Monday, October 16th. Zacks Investment Research upgraded Iqvia from a “hold” rating to a “buy” rating and set a $107.00 target price on the stock in a research report on Wednesday, October 11th. Mizuho cut Iqvia from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Thursday, November 9th. Finally, TheStreet upgraded Iqvia from a “c+” rating to a “b” rating in a research report on Wednesday, December 13th. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $107.55.

Iqvia (IQV) traded up $0.78 during midday trading on Monday, reaching $103.78. The company’s stock had a trading volume of 727,168 shares, compared to its average volume of 1,110,854. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.22 and a quick ratio of 1.22. Iqvia has a 52 week low of $74.80 and a 52 week high of $110.67. The firm has a market cap of $21,470.00, a PE ratio of 357.86, a price-to-earnings-growth ratio of 1.42 and a beta of 0.61.

Iqvia (NYSE:IQV) last released its earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.05. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The company had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the previous year, the firm posted $1.00 EPS. The firm’s quarterly revenue was up 77.6% on a year-over-year basis. research analysts predict that Iqvia will post 4.62 earnings per share for the current year.

In related news, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $102.00, for a total value of $764,776,314.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Connaughton sold 1,163,191 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $102.00, for a total value of $118,645,482.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,806,558 shares of company stock worth $898,716,708. Insiders own 6.40% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Winslow Evans & Crocker Inc. acquired a new stake in shares of Iqvia in the 4th quarter worth approximately $123,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Iqvia in the 4th quarter worth approximately $209,000. Atria Investments LLC purchased a new stake in Iqvia in the 4th quarter valued at approximately $218,000. Fox Run Management L.L.C. purchased a new stake in Iqvia in the 4th quarter valued at approximately $250,000. Finally, Creative Planning purchased a new stake in Iqvia in the 4th quarter valued at approximately $450,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/22/iqvia-iqv-receives-hold-rating-from-suntrust-banks.html.

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply